CCR8 and neoplasm: Blocking the CCL1-CCR8 axis is another option for Treg depletion in the TME.75 Two recent preclinical studies demonstrated that anti-CCR8 antibodies with Fc-dependent ADCC activity selectively deplete tumor-infiltrating Tregs due to prominent CCR8 expression by the activated Tregs in the TME, leading to long-lasting antitumor immune responses and synergistic antitumor effects with PD-1 blockade.130 131